Schering-Plough Gets EU OK for Temodal

Drugmaker Schering-Plough Corp. said that it received European approval to market its chemotherapy drug Temodal as a first-line treatment for the most common form of brain cancer. The company said the drug was approved to treat glioblastoma multiforme, an aggressive form of cancer that attacks the central nervous system, most often in the cerebrum. The disease is the most common and deadliest type of brain cancer. The approval covers the marketing of Temodal for use in combination with radiation therapy in 25 European Union countries as well as in Iceland and Norway.

()a href="http://biz.yahoo.com/ap/050610/schering_plough_temodal.html?.v=1" target="_blank">Yahoo News